ArticleClinical genetics2025
Deep Phenotyping of Pathology-Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients.
Article in Clinical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Deep Phenotyping of Pathology-Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients.Clinical genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PTEN Hamartoma Tumor Syndrome (PHTS) is a rare hereditary syndrome. PHTS has a variable phenotype characterized by benign lesions and increased cancer risks. Clarifying the extent of the benign phenotype could facilitate early recognition of PHTS patients before cancer development. Therefore, we assessed the spectrum, frequency, and age of excerpt of pathology-confirmed benign lesions in PHTS patients. Pathology reports were collected for 379 patients with a pathogenic PTEN variant from the Dutch nationwide pathology databank (Palga). Benign lesions were classified as PHTS-related based on current clinical diagnostic guidelines and non-PHTS-related lesions by ICD-10 codes. Age of last follow-up was year of pathology request minus birth year. Analyses were stratified by sex and index status. Patients presented mainly with gastrointestinal (54%), skin (47%), thyroid (31%) and vascular lesions (26%). Males developed lipomas at an early age (9 years (5-34)). Females developed endometrial hyperplasia (16%) at an earlier age (41 years (35-49)) and uterine polyps (13%) more often than the general population. No significant differences were observed between sexes or index and non-index patients. The results are reflective of current diagnostic guidelines. Early-onset lipomas may be useful for early detection of PHTS patients. Additionally, uterine polyps should be considered for inclusion as a PHTS-related lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.